Kornimate/medical-research-clean huggingface dataset:
efficacy of a patient education video

Conditions: Leukemia, Not Otherwise Specified; Malignant Neoplasm

Summary: patients in the intervention arm will view the 23-minute video depicting the hematopoietic stem cell transplantation (hsct) experience. patients in the control arm will receive hsct frequently asked questions (faq) sheet developed by the national cancer institute (nci) at the national institutes of health (nih).

the study's overall goals are 1) to improve outcomes; and 2) to increase satisfaction with the physician consultation. patients will be randomized to intervention or control and data will be collected at three time points (before treatment, 30 days post-hsct and 12 months post-hsct).

Eligibility criteria:
inclusion criteria: * cancer patients scheduled for hsct exclusion criteria: * patients who have received hsct previously * patients who do not speak english

Keywords: multiple myeloma
benefits and costs of home-based pulmonary rehabilitation in chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: pulmonary rehabilitation is an effective treatment for people with chronic obstructive pulmonary disease (copd) which improves symptoms, reduces hospitalisation and lowers healthcare costs. however less than 1% of australians with copd receive pulmonary rehabilitation each year, due to poor access to programs and high levels of disability. this randomised controlled trial will examine the benefits and costs of a novel, entirely home-based pulmonary rehabilitation program for copd. we hypothesise that home-based pulmonary rehabilitation can deliver equivalent clinical outcomes at lower cost than the centre-based program. we will randomly allocate 144 people with copd to undertake either standard pulmonary rehabilitation in a hospital setting, or a low-cost home-based program. those who undertake pulmonary rehabilitation in the hospital setting will attend the hospital twice each week for eight weeks for supervised exercise training and education. people in the home pulmonary rehabilitation group will receive one home visit and weekly telephone calls for eight weeks, for supervision and mentoring of exercise and provision of education. we will compare the number of people who complete the program in each setting. we will also test whether the groups have similar results for the standard pulmonary rehabilitation outcomes of breathlessness, quality of life and exercise capacity, at the end of the program and 12 months later. we will compare health care costs and personal costs between groups after 12 months. if home-based pulmonary rehabilitation can improve uptake of this important treatment, deliver good clinical outcomes and reduce costs this will have significant and long-lasting benefits for patients, the community and the health system


Eligibility criteria:
inclusion criteria: * current or former smokers of at least 10 packet years * aged 40 years or over * diagnosis of copd confirmed on spirometry. exclusion criteria: * previous diagnosis of asthma * have attended a pulmonary rehabilitation program in the last two years * exacerbation of copd within the last four weeks * have comorbidities which prevent participation in an exercise training program

Keywords: copd exercise rehabilitation dyspnea quality of life economic evaluation
endoscopic lung volume reduction in patients with advanced emphysema due to alpha1 antitrypsin deficiency

Conditions: Hereditary Emphysema (Alpha 1-antitrypsin Deficiency)

Summary: patients with advanced heterogeneous emphysema due to alpha1 antitrypsin deficiency might benefit from endoscopic implantation of intrabronchial valves.

patient enrollment and data acquisition is to be carried out on a prospective basis. it is planned to enroll a total of 25 patients with advanced heterogeneous emphysema due to alpha1 antitrypsin deficiency. all patients will undergo treatment at one study centre in heidelberg. therapy of all patients consists of implantation of intrabronchial valves (ibv, spiration, olympus) in the most emphysematous destroyed lobe.

Eligibility criteria:
inclusion criteria: * pulmonary function: fev1 \ 150 %, tlc \> 100 % * alpha1 antitrypsin deficiency (\< 80 mg/dl), genotype: pizs, pizz, pi0/0 * heterogenous emphysema exclusion criteria: * homogenous emphysema * significant bronchiectasis * severe concomitant diseases * pregnancy

Keywords: emphysema alpha1 antitrypsin deficiency endoscopic lung volume reduction
a time-limited approach to treatment with ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma

Conditions: CLL; SLL; CLL/SLL; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Summary: the purpose of this study is to find out whether people with cll or sll who are currently receiving treatment with ibrutinib can stop treatment and remain off-treatment for at least 12 months, if they have achieved complete or partial remission of their disease.


Eligibility criteria:
inclusion criteria: * ≥ 18-years-old * diagnosis of cll or sll confirmed by the enrolling institution * negative del(17p) test confirmed by fish testing prior to initiating treatment with ibrutinib * receiving commercial treatment with an ibrutinib-based regimen in the front-line setting as defined below with the intent to discontinue therapy on c1d1: 1. ibrutinib monotherapy 2. ibrutinib in combination with anti-cd20 monoclonal antibody (patients must have completed the anti-cd20 monoclonal antibody portion of the regimen prior to signing consent) * patients must have received ibrutinib-based therapy for at least 15 months. dose interruptions and reductions during this treatment period may have been carried out per treating provider discretion. * response evaluation performed by radiology assessment (ct or mri imaging of neck / chest / abdomen / pelvis) confirming complete remission or partial remission by iwcll criteria. * peripheral blood (by flow cytometry per institutional standards) testing for mrd confirming u-mrd to a sensitivity of 10\^-4. mrd testing must be confirmed to follow eric consensus criteria. 1. cr with or without u-mrd in peripheral blood 2. pr with u-mrd in peripheral blood exclusion criteria: * any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.. * unwilling or unable to participate in all required study evaluations and procedures. unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (icf) and authorization to use protected health information (in accordance with national and local patient privacy regulations).

Keywords: small lymphocytic lymphoma chronic lymphocytic leukemia cll/sll sll cll ibrutinib ibrutinib monotherapy anti-cd20 monoclonal antibody mrd u-mrd 20-284 memorial sloan kettering cancer center
comparison of desflurane anesthesia versus tiva-tci in patients undergoing ophthalmic ambulatory surgery

Conditions: Ophthalmic; Surgery; Anesthesia

Summary: this is a single-center, randomized, prospective research which aims to investigate the advantages and disadvantages between desflurane balanced anesthesia and tiva-tci with propofol in ophthalmic ambulatory surgery, so that to evaluate a better anesthesia method in ophthalmic surgery through a large sample clinical study.

desflurane balanced anesthesia and tiva-tci(total intravenous anesthesia-target controlled infusion) are commonly used in ophthalmic ambulatory surgery, however, there is no clear evidence to discriminate the advantages and disadvantages between them. this study is designed to evaluate a better anesthetic method in ophthalmic surgery through a clinical study. this is a single center, randomized, prospective study. 200 patients with american society of anesthesiologists'(asa) physical status 1 to 2, aged 18 to 60, scheduled for elective strabismus ambulatory and in whom a lma is indicated for anesthesia are recruited. enrolled patients are randomly assigned into 2 groups: group tiva (tiva-tci with propofol) and group des (desflurane).in group tiva, anesthesia is maintained with propofol and remifentanil. propofol is continuously administered via a target-controlled infusion (tci) pump intraoperatively. in group des, anesthesia is maintained with desflurane.all patients received anaesthesia depth monitoring with bispectral index (bis). the dose of anesthetic is adjusted to maintained the bis value within 40 to 60. at the end of the surgery, inhalant anesthetic or infused propofol and remifentanil are discontinued. lma is removed when patient regains consciousness with spontaneous respiration. patients are then transferred to the post anesthetic care unit (pacu) for postoperative follow-up. the primary outcome is awake time, the secondary outcomes include discharge time, the stay time in pacu, time of off-bed, riker sedation agitation score (sas), time of padss\>9, nrs score when leaving pacu, incidence of various complications (postoperative nausea and vomiting (ponv), emergence agitation, etc), as well as anesthesia cost. all patients are followed up by calling in one day after the surgery.

Eligibility criteria:
inclusion criteria: * 18-60 years patients undergoing selective ophthalmic ambulatory surgery； * asa i and ii * duration of anesthesia at least 30min * without apparent organ comorbidities * sign the informed consent form exclusion criteria: * equal or greater than asa iii * has a history of dementia，psychiatric disorders or central nervous system diseases * taking sedatives, antidepressant or glucocorticoid * without family members * has cardiac, respiratory，liver，kidney comorbidities * uncontrolled hypertension（\>180/100mmhg） * laryngeal mask fail to insert, and change to tracheal intubation

Keywords: ambulatory surgery ophthalmic inhalation anesthesia desflurane total intravenous anesthesia
development of a remote therapy protocol for upper limb function enhancement in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: the perpose of this study: development and demonstration of a teletherapy protocol to improve upper limb function in children with cerebral palsy.

* development of a home-based remote upper limb function evaluation program using heterogeneous (multimodal) sensors. * development of a home-based remote upper limb function improvement treatment program using heterogeneous sensors.

Eligibility criteria:
inclusion criteria: * age 6 to 12 years * macs level 1-4 * diagnosed with cp due to central nervous system lesions exclusion criteria: * individuals with a manual ability classification system (macs) level v, indicating an inability to use both hands in daily life activities. * individuals who fall within levels 0 to 4 of the house functional classification system. * individuals with severe intellectual disabilities, characterized by difficulties in understanding or following instructions. * individuals with vision impairment that could affect participation in the therapy. * individuals who have received a botulinum toxin injection in the upper extremity within the past 6 months.

Keywords: cerebral palsy physical activity telerehabilitation accelerometer
juice plus supplement clinical trial

Conditions: Cognitive Impairment; Alzheimer Disease, Early Onset; Mild Cognitive Impairment

Summary: the study is designed to determine whether encapsulated fruit and vegetable juice concentrates can improve biological indicators of cognitive and multiple dimensions of memory and learning.

preventive interventions that delay the onset of mild cognitive impairment and benign forgetfulness have the potential to delay or even prevent the onset of alzheimer's disease. however, few studies have examined the feasibility of encapsulated fruit and vegetable juice concentrates in robust clinical trials; this limitation prevents investigators from determining the real value of these supplements. therefore, we propose to enroll 150 adults aged 55 and older to a 24-month randomized placebo-controlled trial. participants enrolled in the experimental condition will be encouraged to consume 6 encapsulated fruit and vegetable juice concentrates capsules per day and 33 grams of a soy-based beverage power per day, which included 5 grams of fiber. participants enrolled in the controlled condition will receive six placebo capsules and encouraged to maintain an adequate diet. primary outcomes will include objective measures of cognition, and a panel of inflammatory markers, peptides, enzymes, and other biological markers known to be associated with cognitive decline.

Eligibility criteria:
inclusion criteria: * • men and women ≥55 years old will be eligible participants exclusion criteria: * prior neurological or psychiatric condition * using medications or supplements that influence cognition or inflammation (e.g., nootropics, asprin, and nonsteroidal anti-inflammatory drugs,), * prior cancer diagnosis, * major respiratory, kidney, liver, and gastrointestinal issues * currently enrolled in a weight loss program or taking an appetite suppressant; * current smokers or excessive alcohol users * consume \>= 4 servings of fruits and vegetables per day * participate in \>= 90 minutes of purposeful physical activity per week * do not have a mobile phone * do not have a data plan or regular wireless network

Keywords: fruits and vegetables inflammation cognition
suprathel® use during prolonged field care to promote healing and reduce the need for grafting of burn wounds

Conditions: Wound of Skin; Burns

Summary: the purpose of this study is to determine the effect to which suprathel® (polymedics innovations gmbh, denkendorf, germany) can reduce the need for grafting compared to standard of care (soc). furthermore, the study intends to evaluate if suprathel® allows for a reduction of reduction of pain, infection, provider workload, scar development and costs compared to soc.

we are advocating the study of suprathel® (polymedics innovations gmbh, denkendorf, germany), a synthetic wound dressing made of polymers of d-,l- lactate, and ε caprolactone, in the early coverage of burns for use in large scale combat operations (lscos) as compared to standard of care. the rationale for studying suprathel® is its favorable physical characteristics as a portable treatment, ease of application by personnel without formal medical training, proven efficacy in improving outcomes after partial-thickness burn injury to include better pain control, preliminary evidence in decreasing burn wound conversion, and the lack of adverse consequences in covering indeterminant depth or full thickness burns.

Eligibility criteria:
inclusion criteria: * male or female ≥18 years and ≤75 years * acute partial thickness burns by friction, contact, scalding from hot liquids and flame * tbsa total ≥2 %; burn treatment region of interest: all areas with partial-thickness burns excluding face, neck, scalp, and feet * tbsa 3rd ≤5 % (not to be included as burn treatment region of interest) * subject is able and willing to sign informed consent or via legally authorized representative exclusion criteria: * study wound due to electrical, radioactive, or frostbite-related injury * infection of wounds in the study area at admission per investigator or treating physician discretion * pregnancy/lactation * subjects who are unable to follow the protocol or who are likely to be non-compliant * participation in an active treatment arm of a burn wound related interventional study within 90 days of screening visit or during the study * prisoners * life expectancy less than 6 months * subjects who are receiving steroids, chronic anticoagulants, or immune suppressive treatment
cgb-400 for the reduction of facial redness

Conditions: Rosacea

Summary: open-label multicenter study using cgb-400 gel (cosmetic) to reduce facial redness

this is a open-label multicenter study to evaluate the ability of cgb-400 gel to reduce facial redness typically associated with rosacea. approximately 25 subjects will be enrolled. subjects will receive study treatment for 4 weeks and attend a total of 4 study visits (bl, w1, w2, w4).

Eligibility criteria:
inclusion criteria: 1. outpatient, male or female of any race, 18 years of age or older. female subjects of childbearing potential must have a negative upt at baseline and practice a reliable method of contraception throughout the study. 2. facial redness associated with rosacea. 3. facial redness (iga-r) score of 2 or 3 (i.e., mild or moderate). 4. absence of any skin conditions that could interfere with the visual erythema assessments. 5. willing to forego any other topical or non-topical treatment on the study areas during treatment (other than sun protection or the study specified face wash and moisturizer). 6. willing to use the provided skincare regimen (e.g., face wash and moisturizer) over the duration of the study. 7. sign the irb-approved icf (which includes hipaa) prior to any study-related procedures being performed. exclusion criteria: 1. known hypersensitivity or previous allergic reaction to any constituent of the investigational products (i.e., essential oils, fragrance, choline, phosphatidylcholine, etc.). 2. any transient flushing syndrome. 3. history of basal cell carcinoma within 6 months of visit 1. 4. history or presence of a skin condition/disease that is located in the treatment area(s) and might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, psoriasis, significant actinic damage, vitiligo, open wounds, infection, etc.). 5. diagnosis of severe rosacea, ocular rosacea, rhinophymatous rosacea, or acne fulminans at baseline. 6. blepharitis/meibomianitis requiring systemic treatment by an ophthalmologist. 7. uncontrolled systemic disease. 8. foreseen unprotected and intense/excessive uv exposure during the course of the study. 9. use of any of the following concomitant medications/procedures: * cosmetic and/or otc products for redness reduction and/or skin clearing * topical medications for rosacea * systemic antibiotics or corticosteroids * topical antibiotics, corticosteroids, or antiparasitic agents * intense/excessive ultraviolet (uv) radiation * phototherapy, energy-based therapy, facials, chemical peels, microdermabrasion 10. exposure to any other investigational drug/device within 30 days prior to study entry.
acquired methemoglobinemia observational registry

Conditions: Methemoglobinemia, Acquired; Methemoglobinemia

Summary: this prospective, observational registry aims to collect real-world data regarding the safety and efficacy of provayblue® (methylene blue 0.5%) used according to normal standard of care for the treatment of acquired methemoglobinemia. methylene blue has been used for decades as a rescue medication for the treatment of methemoglobinemia, a rare and potentially life-threatening condition in which elevated levels of methemoglobin impede the delivery of oxygen from blood to body tissues. however, consistent prospective data about the safety and efficacy of this medication are sparse, simply because of the rarity of the disorder. provayblue® received accelerated fda approval for treatment of acquired methemoglobinemia in 2016. this large, prospective, multi-center observational registry has been initiated to gain more information on the use of methylene blue in the treatment of acquired methemoglobinemia.


Eligibility criteria:
inclusion criteria: * adult or pediatric patients diagnosed with acquired methemoglobinemia and receiving treatment with provayblue® (methylene blue 0.5%) as per the treating physician's diagnosis and the acute care facility's standard of care * those acquired methemoglobinemia patients whose diagnosis is aided by measurement of methemoglobin and whose ongoing treatment is guided by re-measurement of methemoglobin \~1h post-treatment with provayblue® in accordance with the us fda label prescribing information exclusion criteria: * refusal of consent (in those subjects approached for consent where required by local institutional procedures) * treatment of methemoglobinemia with another methylene blue product

Keywords: methylene blue
physical activity on prescription in overweight older adults

Conditions: Low Physical Activity Level; Central Obesity; Metabolic Syndrome

Summary: this randomized controlled study evaluates the effect of individualized physical activity on prescription (pap) in older overweight adults. the primary hypothesis is that an individualized prescription of physical activity increases physical activity level in overweight older adults after 6 months. secondary hypothesis are that the increased physical activity level will improve cardio metabolic risk factors and quality of life. 200 women and men, aged 65 with low physical activity level, overweight, and abdominal obesity, will be randomized to an intervention group or a control group. the control group receives general information about physical activity and registration of physical activity level for one week. the intervention group receives in addition an individualized physical activity on prescription with patient-centered counseling. after six months both groups go through the same health check-up as at baseline and follow-ups take place after 12 and 24 months.


Eligibility criteria:
inclusion criteria: * bmi between 25 and 40 * waist circumference over 88 cm for women and 102 cm for men * basically healthy * mostly sedentary in their leisure time exclusion criteria: * current heart disease * tablet or insulin treated diabetes type 2 * cancer * other chronic serious illness
influence of pupillary behavior during eye surgery on morphological and functional outcome

Conditions: Cataract; Corneal Disease; Vitreous Disorder

Summary: pupillary movement during eye surgery can be a challenge for eye surgeons. despite the risk of intraocular lens damage and malpositioning due to mechanical manipulation1, iris manipulation may lead to a significant elevation of cytokines in the aqueous humor and an increase of postoperative inflammation2, 3. iris damage is also known to lead to an increase of prostaglandin production which will not only lead to an increase of inflammation but also has an impact on intraoperative miosis4. this leads to the assumption that postoperative inflammation can be related to intraoperative pupillary movements due to the same leading cause of an increase of inflammatory mediators. tracking intraoperative pupillary movements might therefore be a helpful tool for the prediction of postoperative pcme and could have an impact on therapeutic decisions after surgery.


Eligibility criteria:
inclusion criteria: * presence of significant cataract, * written consent. * presence of other ocular conditions requiring surgery such as: degenerative corneal disease, retinal conditions (i.e. macular pucker) exclusion criteria: - reasons for poor video quality (such as poor red reflex due to abnormal anatomy)

Keywords: cataract refractive surgery vitrectomy
predictive factors for a clinical diagnosis of irritable bowel syndrome in a large cohort of young adults.

Conditions: Irritable Bowel Syndrome

Summary: the prevalence of ibs in the community has been reported in numerous cross-sectional surveys. however, less is known about the incidence of ibs ,mainly due to its slow development and to patients under-reporting. furthermore, only one study has analyzed data concerning potential risk factors for the diagnosis of ibs. the investigators will examine the incidence of ibs in a large cohort of young adults and will look at the association of socioeconomic, anthropometric and occupational factors with ibs incidence.


Eligibility criteria:
inclusion criteria: * all israeli men and women * aged 18-39 years * served in active military service (mandatory and career service) between the years 2005-2011 exclusion criteria: * diagnosis of celiac disease * inflammatory bowel disease * cancer in the digestive system

Keywords: irritable bowel syndrome epidimiology deterioration in the severity of irritable bowel syndrome